US pharma giant is unhappy with Germany; CEO calls planned healthcare reform ‘terrible’
Eli Lilly is halving a €2.3 billion investment in Germany, citing dissatisfaction with the country's proposed healthcare cost-cutting legislation. CEO Dave Ricks warned that the new price framework makes Germany less competitive for pharmaceutical investment.
Why it matters
This reflects a significant conflict between global pharmaceutical giants and European governments over drug pricing and industrial policy.
US pharma giant Eli Lilly is very unhappy with Germany; CEO calls its planned healthcare reform: Terrible signal to ... - The Times of India
The article presents the company's grievances alongside the government's stated goals for the legislation.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in